Lancet Diabetes & Endocrinology

Article	Citations
Paisan Ruamviboonsuk: saving sight in Thailand	857
Vitamin D supplementation and mortality	728
Empagliflozin in adults hospitalised with COVID-19: a (null) hypothesis for RECOVERY	488
Madelung's disease in a rare 14th century Franco-Flemish woolen tapestry	429
Challenges in implementing nationwide epidemiological studies on metabolic non-communicable diseases in low-income and middle-income countries	398
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial	382
Metabolic non-communicable diseases in India: time to act	381
Shahrad Taheri: putting patients' needs first	344
Automated insulin delivery during the first 6 months postpartum (AiDAPT): a prespecified extension study	320
Food and class: a peculiarly British affair	306
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study – Authors' reply	302
Association of glycaemic index and glycaemic load with type 2 diabetes, cardiovascular disease, cancer, and all-cause mortality	299
Current insights and emerging trends in early-onset type 2 diabetes	261
Youth-onset type 2 diabetes among First Nations young people in northern Australia: a retrospective, cross-sectional study	252
Postsurgical radioiodine ablation in low-risk differentiated thyroid cancer	251
Ashley Grossman: finding a calling in neuroendocrinology	244
Mark Atkinson: bringing two worlds together	242
Vitamin D to prevent acute respiratory infections	226
Action framework on healthy food: a way forward for the public sector	209
Fetal growth patterns as early markers of fetal programming	205
Perfluoroalkyl and polyfluoroalkyl substances: the price of forever chemicals	201
Tackling childhood obesity in low-socioeconomic status communities: what is the next step?	200
Implications of technology guidelines for low-income and middle-income countries	185
Diabetes and the WHO Model List of Essential Medicines	171
The human factor	169

Insulin for all: a hope yet to be realised	159
May Ng: a lifetime commitment to children	156
A framework for improving diabetes care in humanitarian emergencies	153
Semaglutide for obesity: four STEPs forward, but more to come	147
A community-based, multi-level, multi-setting, multi-component intervention to reduce weight gain among low socioeconomic status Latinx children with overweight or obesity: The Stanford GOALS randomis	147
Effect of the COVID-19 pandemic on body weight in people at high risk of type 2 diabetes referred to the English NHS Diabetes Prevention Programme	143
Big babies, small babies: metformin exposure in pregnancy	140
People with type 1 diabetes and chronic kidney disease urgently need new therapies: a call for action	138
Data processing in the DMagic cluster randomised controlled trial	138
Milestone achievement for global access to blood glucose meters and test strips	137
South Africa to produce insulin for Africa in 2024	135
Association of age with gaps in diabetes-related care and hospitalisations from childhood to young adulthood in Quebec, Canada: a cohort study	127
Reducing sodium intake: step-by-step targets yield success	121
Thought for food: a Cushing's syndrome enigma explained	115
Newer antidiabetic agents: at what price will they be cost effective?	110
Progress in diabetes prevention or epidemiology—or both, or neither?	110
The growing clinical effect of SGLT2 inhibitors	107
Mendelian randomisation and vitamin D: the importance of model assumptions	106
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes – Authors' reply	101
Targeting RET-mutated thyroid and lung cancer in the personalised medicine era	101
Banning diabetes blanket bans	101
Hot topics on insulin access: the issue of thermostability	100
Long-term trial outcomes of Roux-en-Y gastric bypass and one anastomosis gastric bypass: tipping the scale	100
Anand Hardikar: a scientific nomad searching for the truth	99
Gender disparities in publishing: from words to actions	98
The food system: hunger for change	96
Effect of sodium–glucose co-transporter-2 inhibitors on survival free of organ support in patients hospitalised for COVID-19 (ACTIV-4a): a pragmatic, multicentre, open-label, randomised, controlled, p	95
Cardiovascular morbidity and mortality in patients in Wales, UK with resistance to thyroid hormone β (RTHβ): a linked-record cohort study	94
Associations between reductions in routine care delivery and non-COVID-19-related mortality in people with diabetes in England during the COVID-19 pandemic: a population-based parallel cohort study	93
Post-exercise recovery for the endurance athlete with type 1 diabetes: a consensus statement	91
What's in a decade?	85
Metastases to the thyroid gland: how does this affect cytohistological diagnoses?	85
Call for prospective studies of continuous glucose monitoring to define the glycaemic response to bariatric surgery	84
GLP1 receptor agonists: from antihyperglycaemic to cardiovascular drugs	82
A compass for navigating the perils of hypertriglyceridaemia	81
Better testing and labelling of drugs for people with obesity	78
Impact of BMI on COVID-19 vaccine effectiveness	76
GLP-1 analogue therapy for obesity in people from Asia	75
Trends in leading causes of hospitalisation of adults with diabetes in England from 2003 to 2018: an epidemiological analysis of linked primary care records	73
Tirzepatide adds hepatoprotection to its armoury	73
Direct-to-consumer services: improving access to care for people with diabetes and obesity	73
What's preventing us from curbing the obesity crisis?	73
Tight versus liberal blood-glucose control in the intensive care unit: special considerations for patients with diabetes	72
Sleep: a neglected public health issue	72
Blood pressure reduction and major cardiovascular events in people with and without type 2 diabetes	68
Glucose intolerance in pregnancy and risk of early-onset type 2 diabetes: a population-based cohort study	66
Effects of empagliflozin on estimated extracellular volume, estimated plasma volume, and measured glomerular filtration rate in patients with heart failure (Empire HF Renal): a prespecified substudy o	66
Singapore's “War on Diabetes”	64
Childhood cancer survival: a gap in need of closing	64
Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial	63

World Health Assembly ratifies first global diabetes targets	63
Evaluation of a type 2 diabetes remission programme	62
Obesity in people living with type 1 diabetes	60
Setmelanotide for the treatment of severe early-childhood genetic obesity	60
Evaluation of a type 2 diabetes remission programme – Authors' reply	59
Dulaglutide for erectile dysfunction in type 2 diabetes	59
Setmelanotide: new promise for the treatment of hypothalamic obesity?	58
Forecasting therapeutic responses by albuminuria and eGFR slope during the DAPA-CKD trial	53
SGLT2 inhibitors in clinical practice	52
Measuring serum testosterone in women	50
The potential role for artificial intelligence in fracture risk prediction	49
Adrenal myelolipomas	48
Impact of COVID-19 on diagnoses, monitoring, and mortality in people with type 2 diabetes in the UK	48
Associations of the glycaemic index and the glycaemic load with risk of type 2 diabetes in 127 594 people from 20 countries (PURE): a prospective cohort study	47
The growing global burden of thyroid cancer overdiagnosis	46
Data-driven subgroups of type 2 diabetes, metabolic response, and renal risk profile after bariatric surgery: a retrospective cohort study	46
Diabetes and the WHO Model List of Essential Medicines	46
Risk and course of SARS-CoV-2 infection in patients treated for hypothyroidism and hyperthyroidism	45
Osteopenia: a key target for fracture prevention	45
Outcomes in children of women with type 2 diabetes exposed to metformin versus placebo during pregnancy (MiTy Kids): a 24-month follow-up of the MiTy randomised controlled trial	44
National UK guidelines for the management of paediatric craniopharyngioma	42
Vitamin D supplementation to prevent acute respiratory infections: a systematic review and meta-analysis of aggregate data from randomised controlled trials	42
Associations between body-mass index and COVID-19 severity in 6·9 million people in England: a prospective, community-based, cohort study	41
PCSK9 inhibition with orally administered NNC0385-0434 in hypercholesterolaemia: a randomised, double-blind, placebo-controlled and active-controlled phase 2 trial	40
Metabolic non-communicable disease health report of India: the ICMR-INDIAB national cross-sectional study (ICMR-INDIAB-17)	40
Obesity in the USA: diet and lifestyle key to prevention	39
Estimating the total incidence of type 1 diabetes in children and adolescents aged 0–19 years from 1990 to 2050: a global simulation-based analysis	39
Dapagliflozin and new-onset type 2 diabetes in patients with chronic kidney disease or heart failure: pooled analysis of the DAPA-CKD and DAPA-HF trials	39
The relevance of T3 in the management of hypothyroidism	39
Management of thyroid nodules	39
New metrics to support diabetes education and advocacy	38
The effect of monthly vitamin D supplementation on fractures: a tertiary outcome from the population-based, double-blind, randomised, placebo-controlled D-Health trial	38
Osteoporosis in men	37
Efficacy and safety of the SGLT2 inhibitor empagliflozin versus placebo and the DPP-4 inhibitor linagliptin versus placebo in young people with type 2 diabetes (DINAMO): a multicentre, randomised, dou	36
Effects of subcutaneous tirzepatide versus placebo or semaglutide on pancreatic islet function and insulin sensitivity in adults with type 2 diabetes: a multicentre, randomised, double-blind, parallel	36
Safety and efficacy of once-weekly basal insulin Fc in people with type 2 diabetes previously treated with basal insulin: a multicentre, open-label, randomised, phase 2 study	36
Nutritional intake and bone health	36
Effects of statin therapy on diagnoses of new-onset diabetes and worsening glycaemia in large-scale randomised blinded statin trials: an individual participant data meta-analysis	35
An anti-PCSK9 pill a day to keep cholesterol away: next steps?	35
Sex steroids and the female brain across the lifespan: insights into risk of depression and Alzheimer's disease	35
Correction to Lancet Diabetes Endocrinol 2023; 11: 785–87	34
Correction to Lancet Diabetes Endocrinol 2021; 9: 743–54	33
Correction to Lancet Diabetes Endocrinol 2022; published online Sept 29. https://doi.org/10.1016/S2213-8587(22)00252-2	32
Lomitapide for the treatment of paediatric patients with homozygous familial hypercholesterolaemia (APH-19): results from the efficacy phase of an open-label, multicentre, phase 3 study	32
Global diabetes incidence trends in young adults	32
Correction to Lancet Diabetes Endocrinol 2022; 10: 741–60	32
Disease modifying therapies in diabetes and endocrinology	32
Correction to Lancet Diabetes Endocrinol 2023; 11: 942–54	32
Correction to Lancet Diabetes Endocrinol 2022; 10: 489–98	32
Treatment of type 2 diabetes: challenges, hopes, and anticipated successes	32
Pharmacogenomics of GLP-1 receptor agonists: a genome-wide analysis of observational data and large randomised controlled trials	31
Consensus on diagnosis and management of Cushing's disease: a guideline update	31
Insulin degludec versus insulin detemir, both in combination with insulin aspart, in the treatment of pregnant women with type 1 diabetes (EXPECT): an open‑label, multinational, randomised, controlled	31
Effect of dapagliflozin on the rate of decline in kidney function in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial	30
Effect of the COVID-19 pandemic on surgery for indeterminate thyroid nodules (THYCOVID): a retrospective, international, multicentre, cross-sectional study	30
Lifetime risk, life expectancy, and years of life lost to type 2 diabetes in 23 high-income jurisdictions: a multinational, population-based study	29
C-peptide and metabolic outcomes in trials of disease modifying therapy in new-onset type 1 diabetes: an individual participant meta-analysis	29
Iodine deficiency in Europe: vigilance and action required	28
Correction to Lancet Diabetes Endocrinol 2022; 10: 58–74	28
Food additive emulsifiers and risk of type 2 diabetes	27
Dissection of type 2 diabetes: a genetic perspective	26
Estimating direct tissue effects versus weight loss effects of incretin-based drugs for obesity on various chronic conditions	26
Islet-after-kidney transplantation versus kidney alone in kidney transplant recipients with type 1 diabetes (KAIAK): a population-based target trial emulation in France	26
Hybrid closed-loop insulin therapy and risk of severe hypoglycaemia and diabetic ketoacidosis in young people (aged 2–20 years) with type 1 diabetes: a population-based study	26
Incidence of diabetes after SARS-CoV-2 infection in England and the implications of COVID-19 vaccination: a retrospective cohort study of 16 million people	26
Protein-binding therapy: a new approach to lower cholesterol	26
Diabetes and the WHO Model List of Essential Medicines	25
Nutrition-related health taxes: setting expectations	25
Sodium–glucose co-transporter-2 inhibitors for hospitalised patients with COVID-19: a prospective meta-analysis of randomised trials	25
Stigma in type 1 diabetes: a global problem	24
Glycaemic management in diabetes: old and new approaches	24
Lorenz Hofbauer: connecting the unexpected	24
Challenges in the treatment of young people with type 2 diabetes	24
Jennifer Manne-Goehler: at the crossroads of pandemics	24
Out on a limb: living with diabetes in the Philippines during the pandemic	23
Sylvia Kehlenbrink: facing the extremes	23
The double burden of poor diets	23
New clarity for managing statin intolerance in diabetes	23
National registries as a catalyst to development of diabetes care in low-income and middle-income countries	23
Prioritising COVID-19 over everything: the unintended harm	23

Global thyroid estimates in 2020	22
There is no magic bullet for obesity	22
Revisiting osteoporosis guidelines	22
Explaining the high rate of progression from prediabetes to type 2 diabetes in China	22
Challenging diabetes stigma starts and ends with all of us	22
The uncomfortable truth about kidney disease in type 1 diabetes	22
The TRAVERSE trial: cardiovascular safety of testosterone therapy for older men	22
Black oesophagus in an adolescent with type 2 diabetes	22
The role of nurses in diabetes care: challenges and opportunities	22
Dianna Magliano: at the forefront of change	21
Precision nutrition: a step too far?	21
Association of glycaemic index and glycaemic load with type 2 diabetes in the PURE study	21
Jonathan Valabhji: from clinical practice to policy making and back	21
The deep pockets of health-harming industries	21
Silver Bahendeka: the obligation to hope	20
Biodiversity and its double-edged role in the pathogenesis of type 1 diabetes	20
Semaglutide: weighing up the benefits and risks	19
SARS-CoV-2 and type 1 diabetes in children in Finland: an observational study	19
The epidemiological landscape of thyroid cancer worldwide: GLOBOCAN estimates for incidence and mortality rates in 2020	19
Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study	19
Rising diabetes diagnosis in long COVID	19
Understanding diabetes heterogeneity: key steps towards precision medicine in diabetes	19
Correction to Lancet Diabetes Endocrinol 2024; published online Nov 12. https://doi.org/10.1016/S2213-8587(24)00283-3	18
Effects of empagliflozin on progression of chronic kidney disease: a prespecified secondary analysis from the empa-kidney trial	18
Correction to Lancet Diabetes Endocrinol 2023; 11: 75–76	18
Glucose-lowering drugs with cardiovascular benefits as modifiers of critical elements of the human life history	18
Correction to Lancet Diabetes Endocrinol 2022; 10: 859–68	18
Correction to Lancet Diabetes Endocrinol 2023; 11: 798–810	18
Obesity: what's in a word?	17
Behind the scenes: epigenetic mechanisms rule the roost in pubertal timing	17
Gestational diabetes in Australia: navigating a tsunami	17
The fight to put food on the table: from past to present	17
Iodine status in Iran: from deficient to replete	16
Vitamin D and respiratory infections	16
Comparing the effectiveness of glucose-lowering agents: real-world data to emulate a four-arm target trial – Authors' reply	16
Improving health equity through data collection	16
Metabolic non-communicable diseases in India: time to act – Authors' reply	16
COP27 Climate Change Conference: urgent action needed for Africa and the world	15
Youth gender services: a new model for regional care	15
Can non-equilibrium thermodynamics explain skeletal muscle insulin resistance due to low mitochondrial content?	15
Type 1 diabetes: heterogeneity in heritability	14
An inter-humanitarian agency study of diabetes care and surveillance in humanitarian settings	14
Association between BMI and COVID-19 on hospital budgets	14
The Human Insulin Thermal Solution project—a private sector initiative to address the thermostability of insulin	14
Principles for virtual health care to deliver real equity in diabetes	14
Glycaemic index as part of the diabetes prevention strategy	14
Enteroviruses and risk of islet autoimmunity or type 1 diabetes: systematic review and meta-analysis of controlled observational studies detecting viral nucleic acids and proteins	14
Food additive emulsifiers: a new risk factor for type 2 diabetes?	14
Maria Fleseriu: driving excellence in pituitary care	14
Achieving replicable subphenotypes of adult-onset diabetes	13
Lebanon: insulin out of reach after subsidies lifted	13
Definition and diagnostic criteria of clinical obesity	13